Saturday, January 28, 2023
SCIENMAG: Latest Science and Health News
No Result
View All Result
  • Login
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
No Result
View All Result
Scienmag - Latest science news from science magazine
No Result
View All Result
Home SCIENCE NEWS Medicine & Health

Georgia State University Center for Translational Antiviral Research reports a novel broad-spectrum antiviral drug class with activity against SARS-CoV-2

December 2, 2021
in Medicine & Health
0
Share on FacebookShare on Twitter

Dr. Richard Plemper

Credit: Georgia State University

 

ATLANTA—The COVID-19 pandemic and resurgence of infections by other respiratory RNA viruses such as respiratory syncytial virus (RSV) in children has caused an urgent need for the development of orally available broad-spectrum antiviral therapeutics.

In a study published online on Dec. 2 in Science, researchers in the Institute for Biomedical Sciences at Georgia State University report a new candidate ribonucleoside analog, 4’-fluorouridine (4’-FlU), that has potent antiviral activity against SARS-CoV-2, RSV and other respiratory RNA viruses in cell culture, human organoids and different animal models when administered orally once-daily.

“Mechanistically, we show that 4’-FlU is in a different class from molnupiravir that is currently considered for regulatory approval,” said Dr. Richard Plemper, senior author of the study, Distinguished University Professor and director of the Center for Translational Antiviral Research at Georgia State. “4’-FlU does not act as a mutagen but induces termination of the viral polymerase, aborting replication of the viral genome. There is an urgent need to expand the therapeutic arsenal against SARS-CoV-2 and 4’-FlU has strong developmental promise as a companion drug.”

In the study, 4’-FlU was tested against different SARS-CoV-2 variants of concern in ferrets, which have emerged as a leading model for drug testing, and against respiratory syncytial virus in mice. The researchers found that this drug potently blocked SARS-CoV-2 replication including the gamma and delta variants in the ferret, and efficiently suppressed RSV burden in mouse lungs.

“We are excited that 4’-FlU is the only orally available antiviral candidate currently developed against SARS-CoV-2 that is active when given once-daily,” said Dr. Julien Sourimant, first author of the study and a researcher in Dr. Plemper’s lab in the Institute for Biomedical Sciences, “which should be a major asset in ensuring outpatient compliance.”

This research on 4’-FlU emerged from a collaboration of the team at Georgia State University with researchers at Emory University and the Texas Biomedical Research Institute. The study was funded by public health service grants from the National Institutes of Health/National Institute of Allergy and Infectious Diseases to Georgia State University.

Co-authors of the study include J. Sourimant, C.M. Lieber, M. Aggarwal, R.M. Cox, J.D. Wolf, J.-J. Yeong, M. Toots and R.K. Plemper at Georgia State University; C. Ye and L. Martinez-Sobrido at Texas Biomedical Research Institute; and Z. Sticher, A.A. Kolykhalov, G.R. Bluemling, M.G. Natchus and G.R. Painter at Emory University.



Journal

Science

DOI

10.1126/science.abj5508

Method of Research

Experimental study

Subject of Research

Animals

Article Publication Date

2-Dec-2021

Tags: activityantiviralbroadspectrumCenterclassDrugGeorgiareportsresearchSARSCoV2StatetranslationalUniversity
Share26Tweet16Share5ShareSendShare
  • Logo

    New study shows snacking on mixed tree nuts may impact cardiovascular risk factors and increase serotonin

    71 shares
    Share 28 Tweet 18
  • Ignoring Native American data perpetuates misleading white ‘deaths of despair’ narrative, study finds

    66 shares
    Share 26 Tweet 17
  • Mount Sinai researchers awarded $12 million NIH grant to create a center to unravel novel causes of food allergy and atopic dermatitis

    66 shares
    Share 26 Tweet 17
  • Hydrogen peroxide from tea and coffee residue: New pathway to sustainability

    85 shares
    Share 34 Tweet 21
  • Volcano-like rupture could have caused magnetar slowdown

    64 shares
    Share 26 Tweet 16
  • The next generation of global health innovators: Michelson Prize winners announced

    65 shares
    Share 26 Tweet 16
ADVERTISEMENT

About us

We bring you the latest science news from best research centers and universities around the world. Check our website.

Latest NEWS

Hydrogen peroxide from tea and coffee residue: New pathway to sustainability

Null results research now published by major behavioral medicine journal

Regulating immunological memory may help immune system fight disease, MU study finds

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 205 other subscribers

© 2022 Scienmag- Science Magazine: Latest Science News.

No Result
View All Result
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US

© 2022 Scienmag- Science Magazine: Latest Science News.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In